Skip to main content
Erschienen in: Acta Neurologica Belgica 3/2019

22.10.2017 | Original Article

Early diagnosed cerebrotendinous xanthomatosis patients: clinical, neuroradiological characteristics and therapy results of a single center from Turkey

verfasst von: Tanyel Zubarioglu, Ertugrul Kiykim, Gozde Yesil, Duhan Demircioglu, Mehmet Serif Cansever, Cengiz Yalcinkaya, Cigdem Aktuglu-Zeybek

Erschienen in: Acta Neurologica Belgica | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Cerebrotendinous xanthomatosis (CTX) is a lipid storage disorder caused by defective sterol 27-hydroxylase activity. In spite of subtle clinical signs beginning from childhood, CTX is generally diagnosed lately. The aim of this study is to evaluate clinical, neuroradiological findings and therapy responses of pediatric CTX patients and raise awareness to early features of disease. Patients who were molecularly diagnosed as CTX before 18 years of age were included in study. Clinical, epidemiological, radiological and genotypic features of patients and chenodeoxycholic acid (CDCA) therapy responses were reviewed retrospectively. Six patients were enrolled in the study. The mean age of diagnosis was 11.1 ± 4.5 years. Apart from previous studies, predominance of cerebellar signs over pyramidal signs, peripheral neuropathy with demyelinating neuropathy in majority of patients and pathological brain imaging findings despite young ages of patients were observed. Intention tremor was the consisting finding of all patients. Optic disc drusen was initially reported in one patient. Skeletal system involvement as coarse extremities, deformities and early osteoporosis was recognized in four patients. CDCA therapy improved or at least stabilized neurological functions in all patients. This study is the first CTX series from Turkey and performed among only in early diagnosed patients with a therapy follow-up contrary to limited data in the literature. We suggest that, awareness of intention tremor and ataxic gait in addition to mental retardation, peripheral neuropathy and early osteoporosis can be suspicious for CTX and lead diagnosis. Early treatment can provide stability and may also ameliorate existing neurological findings.
Literatur
1.
Zurück zum Zitat Clayton PT (2016) Disorders of Bile Acid Synthesis. In: Saudubray JM, Baumgartner MR, Walter J (eds) Inborn metabolic diseases: diagnosis and treatment, 6th edn. Springer-Verlag, Heidelberg, pp 465–477CrossRef Clayton PT (2016) Disorders of Bile Acid Synthesis. In: Saudubray JM, Baumgartner MR, Walter J (eds) Inborn metabolic diseases: diagnosis and treatment, 6th edn. Springer-Verlag, Heidelberg, pp 465–477CrossRef
3.
Zurück zum Zitat Federico A, Dotti MT, Gallus GN (2003) Cerebrotendinous Xanthomatosis. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds) GeneReviews Seattle (WA): University of Washington, Seattle, 1993–2017 (updated 2016 Apr 14) Federico A, Dotti MT, Gallus GN (2003) Cerebrotendinous Xanthomatosis. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds) GeneReviews Seattle (WA): University of Washington, Seattle, 1993–2017 (updated 2016 Apr 14)
5.
Zurück zum Zitat Cruysberg JR, Wevers RA, Tolboom JJ (1991) Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis. Am J Ophthalmol 112:606–607CrossRefPubMed Cruysberg JR, Wevers RA, Tolboom JJ (1991) Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis. Am J Ophthalmol 112:606–607CrossRefPubMed
7.
Zurück zum Zitat Verrips A, Hoefsloot LH, Steenbergen GC et al (2000) Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 123:908–919CrossRefPubMed Verrips A, Hoefsloot LH, Steenbergen GC et al (2000) Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 123:908–919CrossRefPubMed
8.
Zurück zum Zitat Cali JJ, Hsieh CL, Francke U, Russell DW (1991) Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266:7779–7783PubMedPubMedCentral Cali JJ, Hsieh CL, Francke U, Russell DW (1991) Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266:7779–7783PubMedPubMedCentral
9.
Zurück zum Zitat Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S (2013) Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol 36:78–83. doi:10.1097/WNF.0b013e318288076a CrossRefPubMed Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S (2013) Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol 36:78–83. doi:10.​1097/​WNF.​0b013e318288076a​ CrossRefPubMed
10.
Zurück zum Zitat Goksen D, Darcan S, Coker M, Kose T (2006) Bone mineral density of healthy Turkish children and adolescents. J Clin Densitom 9:84–90CrossRefPubMed Goksen D, Darcan S, Coker M, Kose T (2006) Bone mineral density of healthy Turkish children and adolescents. J Clin Densitom 9:84–90CrossRefPubMed
11.
Zurück zum Zitat van Heijst AF, Wevers RA, Tangerman A, Cruysberg JR, Renier WO, Tolboom JJ (1996) Chronic diarrhoea as a dominating symptom in two children with cerebrotendinous xanthomatosis. Acta Paediatr 85:932–936CrossRefPubMed van Heijst AF, Wevers RA, Tangerman A, Cruysberg JR, Renier WO, Tolboom JJ (1996) Chronic diarrhoea as a dominating symptom in two children with cerebrotendinous xanthomatosis. Acta Paediatr 85:932–936CrossRefPubMed
12.
Zurück zum Zitat Berginer VM, Gross B, Morad K, Kfir N, Morkos S, Aaref S, Falik-Zaccai TC (2009) Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 123:143–147. doi:10.1542/peds.2008-0192 CrossRefPubMed Berginer VM, Gross B, Morad K, Kfir N, Morkos S, Aaref S, Falik-Zaccai TC (2009) Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 123:143–147. doi:10.​1542/​peds.​2008-0192 CrossRefPubMed
16.
Zurück zum Zitat Hokezu Y, Kuriyama M, Kubota R, Nakagawa M, Fujiyama J, Osame M (1992) Cerebrotendinous xanthomatosis: cranial CT and MRI studies in eight patients. Neuroradiology 34:308–312CrossRefPubMed Hokezu Y, Kuriyama M, Kubota R, Nakagawa M, Fujiyama J, Osame M (1992) Cerebrotendinous xanthomatosis: cranial CT and MRI studies in eight patients. Neuroradiology 34:308–312CrossRefPubMed
17.
Zurück zum Zitat Barkhof F, Verrips A, Wesseling P et al (2000) Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 217:869–876CrossRefPubMed Barkhof F, Verrips A, Wesseling P et al (2000) Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 217:869–876CrossRefPubMed
18.
Zurück zum Zitat Mignarri A, Dotti MT, Federico A et al (2017) The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression. J Neurol 264:862–874. doi:10.1007/s00415-017-8440-0 CrossRefPubMed Mignarri A, Dotti MT, Federico A et al (2017) The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression. J Neurol 264:862–874. doi:10.​1007/​s00415-017-8440-0 CrossRefPubMed
19.
Zurück zum Zitat Federico A, Dotti MT (2003) Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy. J Child Neurol 18:633–638CrossRefPubMed Federico A, Dotti MT (2003) Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy. J Child Neurol 18:633–638CrossRefPubMed
20.
Zurück zum Zitat Federico A, Dotti MT, Lore F, Nuti R (1993) Cerebrotendinous xanthomatosis:pathophysiological study on bone metabolism. J Neurol Sci 115:67–70CrossRefPubMed Federico A, Dotti MT, Lore F, Nuti R (1993) Cerebrotendinous xanthomatosis:pathophysiological study on bone metabolism. J Neurol Sci 115:67–70CrossRefPubMed
21.
Zurück zum Zitat Berginer VM, Shany S, Alkalay D et al (1993) Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism 42:69–74CrossRefPubMed Berginer VM, Shany S, Alkalay D et al (1993) Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism 42:69–74CrossRefPubMed
22.
Zurück zum Zitat Martini G, Mignarri A, Ruvio M et al (2013) Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. Calcif Tissue Int 92:282–286. doi:10.1007/s00223-012-9677-3 CrossRefPubMed Martini G, Mignarri A, Ruvio M et al (2013) Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. Calcif Tissue Int 92:282–286. doi:10.​1007/​s00223-012-9677-3 CrossRefPubMed
25.
Zurück zum Zitat van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ (1998) Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 157:313–316CrossRefPubMed van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ (1998) Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 157:313–316CrossRefPubMed
Metadaten
Titel
Early diagnosed cerebrotendinous xanthomatosis patients: clinical, neuroradiological characteristics and therapy results of a single center from Turkey
verfasst von
Tanyel Zubarioglu
Ertugrul Kiykim
Gozde Yesil
Duhan Demircioglu
Mehmet Serif Cansever
Cengiz Yalcinkaya
Cigdem Aktuglu-Zeybek
Publikationsdatum
22.10.2017
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 3/2019
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-017-0851-2

Weitere Artikel der Ausgabe 3/2019

Acta Neurologica Belgica 3/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.